TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in blood triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach proficiency level on TABLT technical test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute changes in global LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NIH Toolbox Cognition Battery (NIHTB-CB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of positive histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Clinical Remission as Determined by the Partial Mayo Clinic Score (pMCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Endoscopic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Atrial Fibrillation Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaccine-related Grade 3 or 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Objective clinical response (CR or PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time within a blood glucose corridor of 80 - 150 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: residual plasma replication between 0 and 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intracellular HIV RNA levels in circulating lymphocytes (PBMC) and lymphocytes in gut-associated rectal lymphoid tissue (RL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proviral HIV DNA levels in PBMC and RL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physician global assessment of HS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Active Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Unfavorable Structural Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal replacement therapy requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Standard uptake value (SUV) of 18F-FMISO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: k1 parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: k2 parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in number of questions asked concerning prognosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Malnutrition Universal Screening Tool Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of blood C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Services Utilization 3 Months Following Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health Services Utilization 6 Months Following Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health Services Utilization 9 Months Following Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health Services Utilization 12 Months Following Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Health Services Utilization 18 Months Following Hospital Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change From Baseline in Maximum Cystometric Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evaluation of Cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of participants with positive GBS swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: biomarkers and clinical parameters associated with acute coronary syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subclinical Myocardial Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding (requiring more than 2 Red blood cells transfusions)
Endpoint domain: Adverse events/effects
Primary endpoint: Re-exploration for bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: HBV Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: HBsAb Pre-infusion Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discrimination rate of healthy tissue types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean change in VA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anxiety levels as measured by the Multidimensional Anxiety Scale for Children (MASC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression levels as measured by the Beck Depression Inventory for Youth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vessel density of the optic disc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Clinical Chemistry Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in SLP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) based on dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 4 and grade 3 hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Intention to refer to genetic services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Marginal Bone Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 'ON' State From Time of Dosing of APL-130277
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of 'ON' Response From Time of Dosing of APL-130277
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mfERG central ring amplitude density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aura
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HOMA-IR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Acute Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Postnatal depression assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean central macular thickness (CMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological Measures (BRIEF-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neuropsychological Measures (RBANS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neuropsychological Measures (BDI II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutrophil to lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with injection risk behaviour
Endpoint domain: Adverse events/effects
Primary endpoint: Healing of spondylolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intrauterine microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success, Revision, Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Urine output > 0.5 ml/kg/h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Normalization of clinical parameters of simplified PESI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced cortisol secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Minimal Residual Disease (MRD) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Mean Sitting Systolic Blood Pressure (msSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with neurocognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median Percent Change in Weekly absence seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prescriber-confirmed Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive flexibility and processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working memory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels and clearance of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels and clearance of torsemide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels and clearance of codeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels and clearance of talinolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels and clearance of pravastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients in Which the Treatment Was Tolerable
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: infant feeding outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uptake of the Flash-heat method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of Flash-heated breast milk
Endpoint domain: Adverse events/effects
Primary endpoint: Change of intraocular pressure (IOP) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Area under the curve (AUC) of TDF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS) for Prior Week
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Retainment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change of Low Density Lipoprotein (LDL)-Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in AISRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Adverse Events that are potentially device-related
Endpoint domain: Adverse events/effects
Primary endpoint: Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of oncogenic molecular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inflammatory pattern of complement activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complement-regulating proteins (CRegs) on leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transvalvular Mean Pressure Gradient (mPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SLE response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peripheral B-cell tolerance checkpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in B-cell subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in frequency of T-cell phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the production of pro inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the production of anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pupillary light reflex variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systemic Markers of Metabolic Endotoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30 day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of the P3 response to alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective responses to alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of recurrence on postpolypectomy scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue Acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reproducibility of calculated volume of pulmonary masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in condom use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Patients with recurrent anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Alive and free from Grade III/IV intraventricular hemorrhage (IVH) and cystic periventricular leukomalacia (PVL)
Endpoint domain: Mortality/survival
Primary endpoint: Alveolar-arterial (A-a) Gradient change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immune cell populations and HIV-tropic receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from first progression at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients' confirmative responses related to the 12 IEQ-items
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of non-confirmative responses of two raters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood HCV RNA Copies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Detection of deglutitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosed Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Extra-Axial Manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Events Reported as Percentage of Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Overall comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PGA Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Physical Performance as assessed by Short Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ability to perform activities of daily living as assessed by Instrumental Activities of Daily Living questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in cognitive function as assessed by Modified Mini-Mental State Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Transprosthetic pressure gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collection of Endometrial Tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pressure lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Diabetes Self-Efficacy Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Narcotic Consumption
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Symptom Complex Severity (MSCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of Acetylcholine esterase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: occurrence of study related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in intracranial pressure (ICP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-subject Change in Intact Protein Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra-subject Change in Medical Food Protein Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cold pulp test response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax, AUCT and AUC∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaires on nutritional knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Development of SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coefficient of variation of perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically significant findings in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically relevant findings in 12-lead electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Intraocular Pressure Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Natural process of biliary calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary outcome measures
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Child disruptive behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: deep molecular response (Rate of MR4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deep molecular Response (Rate of MR4.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mercury Intoxication Medical Score Sum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEAT (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes